In the ASCERTAIN-V trial, treatment with decitabine/cedazuridine plus venetoclax yielded a complete remission (CR) rate of 41.6% and a CR/CRh rate of 52.5% in patients ineligible for intensive ...
Researchers investigated the link between diabetes status and cancer risk over 10 years among a diverse cohort of Hispanic and Latino adults.
In this study, researchers aimed to investigate whether discontinuing premedications after 2 doses of paclitaxel is safe and feasible in some breast cancer patients.
Beqalzi (sonrotoclax) is the first BCL2 inhibitor indicated for MCL patients who have progressed after at least 2 lines of therapy, including a BTK inhibitor.
This review of studies highlights a call for radiation oncology frameworks that better localize, contour, and spare the ...
The median overall survival was 13.1 months in patients with RAS G12 mutations. Current PDAC therapies provide only modest benefit, study researchers noted. Because activating RAS mutations occur in ...
In 14 of the 17 states in the South region, more than 20% of adolescents were unvaccinated. Southern states have the highest rates of adolescents who have not received the human papillomavirus (HPV) ...
Increasing the visibility and representation of sexual and gender minorities (SGM) in clinical trials is vital for developing evidence-based and tailored care that can eliminate cancer disparities, ...
(HealthDay News) — Prescriptions for the anti-parasite medication ivermectin doubled after actor Mel Gibson endorsed the dewormer as an off-label cancer cure on a high-profile podcast, a new study ...
Financial concerns, inconsistent preventive care, and limited access to credible information are influencing health decisions across life stages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results